Patients with connective tissue disease-associated interstitial lung disease (CTD-ILD) might expect a small improvement in lung function with cyclophosphamide treatment, a Cochrane review has concluded. The systematic review of the limited evidence – just four studies – found the immunosuppressant was associated with a modest but significant benefit in forced vital capacity (FVC) compared to ...
Cochrane Review highlights lack of evidence for ILD treatment
By Mardi Chapman
15 Mar 2018